HR 4299 — Protecting Patient Access to Cancer and Complex Therapies Act
Congress 119
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
- Murphy, Gregory F. (R, NC-3) — sponsor · 2025-07-07
- Harris, Andy (R, MD-1) — cosponsor
- Davis, Donald G. (D, NC-1) — cosponsor
- Gray, Adam (D, CA-13) — cosponsor
- Harrigan, Pat (R, NC-10) — cosponsor
- Miller, Carol D. (R, WV-1) — cosponsor
- Cuellar, Henry (D, TX-28) — cosponsor
Lobbied by (5)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
| Filing | Period | Registrant (lobbying firm) | Client | Income | Matched |
|---|---|---|---|---|---|
| 1st Quarter - Report | 2026 first_quarter | FERRING PHARMACEUTICALS, INC. | FERRING PHARMACEUTICALS, INC. | — | H.R. 4299 |
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | TAKEDA PHARMACEUTICALS AMERICA, INC. | $50,000 | H.R. 4299 |
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | MERCK & CO., INC | $50,000 | H.R. 4299 |
| 1st Quarter - Report | 2026 first_quarter | COMMUNITY ONCOLOGY ALLIANCE | COMMUNITY ONCOLOGY ALLIANCE | — | HR 4299 |
| 1st Quarter - Report | 2026 first_quarter | ASSOCIATION FOR CLINICAL ONCOLOGY | ASSOCIATION FOR CLINICAL ONCOLOGY | — | H.R. 4299 |
Action timeline
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · Intro-H — Introduced in House
- · 1000 — Introduced in House
Text versions
- Introduced in House · 2025-07-07 — open
Connected on the graph
Inbound (12)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | Davis, Donald G. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Gray, Adam | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Miller, Carol D. | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Harrigan, Pat | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Cuellar, Henry | cosponsor_of_bill | — | cosponsor | sponsorship |
| — | Harris, Andy | cosponsor_of_bill | — | cosponsor | sponsorship |
| 2026-01-01 | FERRING PHARMACEUTICALS, INC. | lobbies_on_bill | — | H.R. 4299 | lobbying_bill_mention |
| 2026-01-01 | ASSOCIATION FOR CLINICAL ONCOLOGY | lobbies_on_bill | — | H.R. 4299 | lobbying_bill_mention |
| 2026-01-01 | COMMUNITY ONCOLOGY ALLIANCE | lobbies_on_bill | — | HR 4299 | lobbying_bill_mention |
| 2026-01-01 | TAKEDA PHARMACEUTICALS AMERICA, INC. | lobbies_on_bill | — | H.R. 4299 | lobbying_bill_mention |
| 2026-01-01 | MERCK & CO., INC. | lobbies_on_bill | — | H.R. 4299 | lobbying_bill_mention |
| 2025-07-07 | Murphy, Gregory F. | sponsor_of_bill | — | sponsor | sponsorship |
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Murphy, Gregory F. (R, house NC-3) | sponsor | 1 | — | 6 |
| 2 | Davis, Donald G. (D, house NC-1) | cosponsor | 3 | — | 4 |
| 3 | Gray, Adam (D, house CA-13) | cosponsor | 1 | — | 2 |
| 4 | Cuellar, Henry (D, house TX-28) | cosponsor | 0 | — | 1 |
| 5 | Harrigan, Pat (R, house NC-10) | cosponsor | 0 | — | 1 |
| 6 | Harris, Andy (R, house MD-1) | cosponsor | 0 | — | 1 |
| 7 | Miller, Carol D. (R, house WV-1) | cosponsor | 0 | — | 1 |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 1 | $50,000 | 0 | $0 | $50,000 |
| 2 | MERCK & CO., INC | 1 | $50,000 | 0 | $0 | $50,000 |
| 3 | retired | 0 | $0 | 32 | $14,344 | $14,344 |
| 4 | none | 0 | $0 | 58 | $13,432 | $13,432 |
| 5 | not employed | 0 | $0 | 51 | $11,675 | $11,675 |
| 6 | self employed | 0 | $0 | 14 | $7,533 | $7,533 |
| 7 | dragonfly | 0 | $0 | 1 | $7,000 | $7,000 |
| 8 | berkshire partners | 0 | $0 | 1 | $7,000 | $7,000 |
| 9 | story partners | 0 | $0 | 1 | $7,000 | $7,000 |
| 10 | verano | 0 | $0 | 1 | $6,500 | $6,500 |
| 11 | continental realty corporation | 0 | $0 | 1 | $6,000 | $6,000 |
| 12 | n/a | 0 | $0 | 9 | $5,200 | $5,200 |
| 13 | jushi holdings | 0 | $0 | 2 | $5,000 | $5,000 |
| 14 | university of california berkeley | 0 | $0 | 1 | $5,000 | $5,000 |
| 15 | solil management | 0 | $0 | 1 | $3,500 | $3,500 |
| 16 | ward and smith | 0 | $0 | 1 | $3,500 | $3,500 |
| 17 | method security | 0 | $0 | 1 | $3,500 | $3,500 |
| 18 | thorsen french advocacy | 0 | $0 | 2 | $3,000 | $3,000 |
| 19 | united states hispanic business counci | 0 | $0 | 1 | $2,500 | $2,500 |
| 20 | s&f family office | 0 | $0 | 1 | $2,500 | $2,500 |
| 21 | kelly benefits | 0 | $0 | 2 | $2,000 | $2,000 |
| 22 | kelly & associates insurance group, in | 0 | $0 | 1 | $2,000 | $2,000 |
| 23 | jushi holding | 0 | $0 | 1 | $2,000 | $2,000 |
| 24 | buckeye relief | 0 | $0 | 1 | $2,000 | $2,000 |
| 25 | healthcare | 0 | $0 | 1 | $2,000 | $2,000 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
7 predicted yes (1%) · 3 predicted no (1%) · 533 unknown (98%)
By party: · R: 4 yes / 0 no / 273 unknown · D: 3 yes / 0 no / 260 unknown · I: 0 yes / 3 no
7 high-confidence positions (voted + sponsor + cosponsor)
- Murphy, Gregory F. (R · house · NC-3) · sponsor
- Cuellar, Henry (D · house · TX-28) · cosponsor
- Davis, Donald G. (D · house · NC-1) · cosponsor
- Gray, Adam (D · house · CA-13) · cosponsor
- Harrigan, Pat (R · house · NC-10) · cosponsor
- Harris, Andy (R · house · MD-1) · cosponsor
- Miller, Carol D. (R · house · WV-1) · cosponsor
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-17 · cosponsored by Miller, Carol D. (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Harris, Andy (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Harrigan, Pat (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Cuellar, Henry (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Gray, Adam (cosponsor) · sponsorship
- 2026-05-17 · cosponsored by Davis, Donald G. (cosponsor) · sponsorship
- 2026-01-01 · lobbied on by TAKEDA PHARMACEUTICALS AMERICA, INC. (h.r. 4299) · lobbying_bill_mention
- 2026-01-01 · lobbied on by MERCK & CO., INC. (h.r. 4299) · lobbying_bill_mention
- 2026-01-01 · lobbied on by FERRING PHARMACEUTICALS, INC. (h.r. 4299) · lobbying_bill_mention
- 2026-01-01 · lobbied on by COMMUNITY ONCOLOGY ALLIANCE (hr 4299) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ASSOCIATION FOR CLINICAL ONCOLOGY (h.r. 4299) · lobbying_bill_mention
- 2025-07-07 · sponsored by Murphy, Gregory F. (sponsor) · sponsorship